CurrentAmbetter NevadaPolicy CP.MP.133

Posterior Tibial Nerve Stimulation for Voiding Dysfunction

Customize your policy alerts

Sign up for Ambetter Nevada Policy CP.MP.133 alerts

Get alerted when Policy CP.MP.133 changes without checking for updates manually.

Monitor payer policy activity

Receive email alerts as soon as relevant payer policies are published or updated.

Defines medical necessity criteria, coding guidance, and coverage stance for percutaneous posterior tibial nerve stimulation to treat overactive bladder (OAB) and related voiding dysfunction for Ambetter Nevada members.

Policy Summary

PayerAmbetter Nevada

PolicyPosterior Tibial Nerve Stimulation for Voiding Dysfunction

Policy CodePolicy CP.MP.133

Change TypeRevisions to conservative management examples and coding updates

Effective Date

Next Review Date

Key ActionObtain prior authorization for percutaneous PTNS (CPT 64566) and document diagnosis of OAB, prior failure of conservative management, and planned 12 weekly 30-minute sessions.

SourceLink

POLICY UPDATE CHANGES

Replaced 'investigational' language with 'insufficient evidence to support .'

Revised Criteria I.B. to include examples of behavioral therapies such as bladder training or pelvic floor muscle training and generalized 'medications used with the intent to treat OAB.'

Updated coding and descriptions; CPT coding implications reviewed and updated.

OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

CurrentAmbetter NevadaPolicy CP.MP.133

Posterior Tibial Nerve Stimulation for Voiding Dysfunction

Customize your policy alerts

Sign up for Ambetter Nevada Policy CP.MP.133 alerts

Get alerted when Policy CP.MP.133 changes without checking for updates manually.

Monitor payer policy activity

Receive email alerts as soon as relevant payer policies are published or updated.

Policy Summary

PayerAmbetter Nevada

PolicyPosterior Tibial Nerve Stimulation for Voiding Dysfunction

Policy CodePolicy CP.MP.133

Change TypeRevisions to conservative management examples and coding updates

Effective Date

Next Review Date

Key ActionObtain prior authorization for percutaneous PTNS (CPT 64566) and document diagnosis of OAB, prior failure of conservative management, and planned 12 weekly 30-minute sessions.

SourceLink

POLICY UPDATE CHANGES

Replaced 'investigational' language with 'insufficient evidence to support .'

Revised Criteria I.B. to include examples of behavioral therapies such as bladder training or pelvic floor muscle training and generalized 'medications used with the intent to treat OAB.'

Updated coding and descriptions; CPT coding implications reviewed and updated.

Coverage and Medical Necessity Criteria

inv-01: Initial therapy (percutaneous PTNS) — Covered when ALL of the following are met

Covered when ALL of the following are met

Initial PTNS criteria: A. Diagnosis of overactive bladder (OAB); B. Failure of conservative medical management (e.g., behavioral therapies such as bladder training or pelvic floor muscle training, or pharmacotherapy with oral medications used with the intent to treat OAB), unless conservative management is not desired or is medically contraindicated; C. Service is provided in accordance with the standard treatment regimen of 30-minute weekly sessions for 12 weeks.

Responders often show improvement after 6-8 sessions.

inv-02: Maintenance therapy — Covered when ALL of the following are met

Covered when ALL of the following are met

Maintenance PTNS: Once-a-month maintenance treatments with PTNS are medically necessary for patients who experience significant improvement in their OAB symptoms after the 12 initial treatments. Treatment frequency may vary depending on return of symptoms.

Frequency individualized to symptom recurrence.

inv-03: Not supported / Insufficient evidence

Unsupported indications: Use of PTNS beyond 12 months without evidence of benefit, and implantable tibial nerve stimulation for urinary voiding dysfunction lack sufficient evidence to support use.

Implantable devices remain insufficient evidence per policy.

Implantable tibial nerve stimulation systems — including procedures for implantation or replacement, revision or removal, and electronic analysis/programming of implanted devices — are not supported and are listed as CPT codes that do not support medical necessity. Specific codes include 0587T, 0588T, 0589T, and 0590T. These services lack sufficient evidence in the published literature to meet medical necessity criteria and therefore may be denied when billed for treatment of urinary voiding dysfunction.

The policy states there is insufficient evidence to support the use of implantable tibial nerve stimulation for treatment of urinary voiding dysfunction. As a result, implantable PTNS devices and their associated procedures are considered not medically necessary for this indication and are explicitly identified in the policy’s non-covered CPT list.

Coding Guidance

CPT codes that support medical necessityCPTCovered

64566

Posterior tibial neurostimulation, percutaneous needle electrode, single treatment, includes programming

CPT codes that do not support medical necessity (implantable systems/programming)CPTNot Covered

0587T	Percutaneous implantation or replacement of integrated single device neurostimulation system for bladder dysfunction including electrode array and receiver or pulse generator, including analysis, programming and imaging guidance when performed, posterior tibial nerve.
0588T	Revision or removal of percutaneously placed integrated single device neurostimulation system for bladder dysfunction including electrode array and receiver or pulse generator, including analysis, programming, and imaging guidance when performed, posterior tibial nerve.
0589T	Electronic analysis with simple programming of implanted integrated neurostimulation system for bladder dysfunction (eg, electrode array and receiver), including contact group(s), amplitude, pulse width, frequency (Hz), on/off cycling, burst, dose lockout, patient-selectable parameters, responsive neurostimulation, detection algorithms, closed-loop parameters, and passive parameters, when performed by physician or other qualified health care professional, posterior tibial nerve, 1-3 parameters.
0590T	Electronic analysis with complex programming of implanted integrated neurostimulation system for bladder dysfunction (eg, electrode array and receiver), including contact group(s), amplitude, pulse width, frequency (Hz), on/off cycling, burst, dose lockout, patient-selectable parameters, responsive neurostimulation, detection algorithms, closed-loop parameters, and passive parameters, when performed by physician or other qualified health care professional, posterior tibial nerve, 4 or more parameters.

inv-08: Initial treatment course — 12 weekly 30-minute sessions (key treatment parameters)

Standard regimen12 weekly sessions of posterior tibial nerve stimulation

Session durationEach session is 30 minutes of stimulation

Typical response timeframeResponders often show improvement after 6–8 sessions

Stimulation parametersLow-voltage stimulation at 0.5–9 mA and ~20 Hz per session

Provider Requirements and Authorization

Prior Authorization

Prior Authorization Required

Prior authorization is required for percutaneous posterior tibial nerve stimulation (PTNS) when billed with CPT 64566. Requests should document diagnosis of overactive bladder (OAB), prior conservative management attempts (unless contraindicated or not desired), and that the planned regimen follows the standard 30-minute weekly sessions for 12 weeks. Monthly maintenance treatments may be considered if the member experiences significant improvement after the initial 12 treatments; frequency may vary based on symptom return.

Affected code: CPT 64566 — Posterior tibial neurostimulation, percutaneous needle electrode, single treatment, includes programming
Prior conservative management required: behavioral therapies (e.g., bladder training, pelvic floor muscle training) or pharmacotherapy unless not desired or medically contraindicated
Standard initial regimen: 30-minute sessions once weekly for 12 weeks
Maintenance: once-monthly treatments may be medically necessary for responders; frequency individualized

Documentation Required

Clinical Background

Overactive bladder (OAB) is a voiding dysfunction characterized by urinary urgency, increased frequency, nocturia, and sometimes urge urinary incontinence; it can substantially reduce quality of life. Posterior tibial nerve stimulation (PTNS) is a minimally invasive neuromodulation technique that delivers low‑voltage electrical stimulation to the posterior tibial nerve via a percutaneous needle electrode near the ankle to modulate sacral nerve activity. Standard initial therapy typically consists of 12 weekly, 30‑minute sessions, and responders may require individualized maintenance treatments (commonly monthly) to sustain benefit.

Key Definitions

inv-14: Overactive bladder (OAB) — definition and core symptoms

DefinitionOveractive bladder (OAB) is a type of voiding dysfunction characterized by urinary urgency, urinary frequency, urge incontinence, and nocturia

ImpactOAB can significantly affect quality of life, including physical, sexual, and social functioning

Common conservative treatmentsLifestyle changes, bladder training, pelvic floor muscle training, and anticholinergic (anti‑muscarinic) medications

inv-15: Posterior tibial nerve stimulation (PTNS) — brief description of the procedure

Procedure descriptionPercutaneous posterior tibial nerve stimulation uses a 34‑gauge needle electrode placed near the posterior tibial nerve (≈5 cm cephalad to the medial malleolus and 2 cm posterior to the tibia) with a surface electrode on the medial foot

Mechanism